Caner SÃ¹/₄sal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8388490/publications.pdf

Version: 2024-02-01

		101496	102432
135	5,017	36	66
papers	citations	h-index	g-index
135	135	135	4312
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation, 2013, 95, 19-47.	0.5	679
2	Antibodies against MICA Antigens and Kidney-Transplant Rejection. New England Journal of Medicine, 2007, 357, 1293-1300.	13.9	386
3	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney International, 2018, 94, 964-973.	2.6	198
4	Identification of Highly Responsive Kidney Transplant Recipients Using Pretransplant Soluble CD30. Journal of the American Society of Nephrology: JASN, 2002, 13, 1650-1656.	3.0	140
5	Kidney graft failure and presensitization against HLA Class I and Class II antigens 1. Transplantation, 2002, 73, 1269-1273.	0.5	133
6	Three-Year Outcomes Following 1420 ABO-Incompatible Living-Donor Kidney Transplants Performed After ABO Antibody Reduction. Transplantation, 2015, 99, 400-404.	0.5	130
7	No Association of Kidney Graft Loss With Human Leukocyte Antigen Antibodies Detected Exclusively by Sensitive Luminex Single-Antigen Testing: A Collaborative Transplant Study Report. Transplantation, 2011, 91, 883-887.	0.5	107
8	Current role of human leukocyte antigen matching in kidney transplantation. Current Opinion in Organ Transplantation, 2013, 18, 438-444.	0.8	104
9	SOLUBLE CD30 AS A PREDICTOR OF KIDNEY GRAFT OUTCOME1. Transplantation, 2002, 73, 3-6.	0.5	102
10	Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients. Transplantation, 2008, 86, 1214-1221.	0.5	102
11	Serial Peripheral Blood Perforin and Granzyme B Gene Expression Measurements for Prediction of Acute Rejection in Kidney Graft Recipients. American Journal of Transplantation, 2003, 3, 1121-1127.	2.6	99
12	Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1073-1082.	2.2	88
13	Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: A Collaborative Transplant Study report. Human Immunology, 2009, 70, 569-573.	1.2	83
14	Influence of Test Technique on Sensitization Status of Patients on the Kidney Transplant Waiting List. American Journal of Transplantation, 2013, 13, 2075-2082.	2.6	83
15	Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection1. Transplantation, 2003, 75, 421-423.	0.5	81
16	The collaborative transplant study registry. Transplantation Reviews, 2013, 27, 43-45.	1.2	79
17	IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transplant International, 2012, 25, 1165-1173.	0.8	77
18	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLoS Medicine, 2018, 15, e1002572.	3.9	76

#	Article	IF	CITATIONS
19	Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation, 2015, 99, 1976-1980.	0.5	7 5
20	ABO-Incompatible Kidney Transplantation. Frontiers in Immunology, 2017, 8, 234.	2.2	73
21	Split liver transplantation: Current developments. World Journal of Gastroenterology, 2018, 24, 5312-5321.	1.4	66
22	ABO-Incompatible Kidney Transplantation Enabled by Non-Antigen-Specific Immunoadsorption. Transplantation, 2012, 93, 827-834.	0.5	59
23	Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transplant International, 2012, 25, 506-517.	0.8	59
24	Molecular Mimicry between HIVâ€1 and Antigen Receptor Molecules: A Clue to the Pathogenesis of AIDS. Vox Sanguinis, 1993, 65, 10-17.	0.7	54
25	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. Therapeutic Drug Monitoring, 2010, 32, 560-572.	1.0	54
26	Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplantation Proceedings, 2004, 36, 29-34.	0.3	50
27	Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines, 2021, 9, 857.	2.1	49
28	Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. International Immunopharmacology, 2003, 3, 1791-1801.	1.7	48
29	An Integrative Approach for the Transplantation of High-Risk Sensitized Patients. Transplantation, 2010, 90, 645-653.	0.5	48
30	Induction of apoptosis in human lymphocytes by the herbicide 2,4-dichlorophenoxyacetic acid. Human Immunology, 2001, 62, 64-74.	1.2	44
31	Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation, 2003, 76, 1231-1232.	0.5	44
32	Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation, 2015, 99, 2364-2371.	0.5	44
33	Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation. Journal of Immunology Research, 2014, 2014, 1-5.	0.9	42
34	HLA Antibodies and the Occurrence of Early Adverse Events in the Modern Era of Transplantation: A Collaborative Transplant Study Report. Transplantation, 2009, 87, 1367-1371.	0.5	40
35	Posttransplant sCD30 as a Predictor of Kidney Graft Outcome. Transplantation, 2011, 91, 1364-1369.	0.5	39
36	Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients. Pediatric Nephrology, 2016, 31, 1157-1166.	0.9	39

#	Article	IF	Citations
37	Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. Nephrology Dialysis Transplantation, 2018, 33, 1065-1072.	0.4	38
38	Expression of Regulatory T–Cell-Related Molecule Genes and Clinical Outcome in Kidney Transplant Recipients. Transplantation, 2009, 87, 857-863.	0.5	37
39	Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. American Journal of Transplantation, 2022, 22, 1873-1883.	2.6	37
40	Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Human Immunology, 2009, 70, 627-630.	1.2	36
41	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. Vaccines, 2021, 9, 1130.	2.1	36
42	The Differential Influence of Cold Ischemia Time on Outcome After Liver Transplantation for Different Indications—Who Is at Risk? A Collaborative Transplant Study Report. Frontiers in Immunology, 2020, 11, 892.	2.2	35
43	Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrology Dialysis Transplantation, 2016, 31, 1360-1367.	0.4	34
44	Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Human Immunology, 2004, 65, 810-816.	1.2	32
45	Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1730-1738.	0.4	32
46	Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. American Journal of Transplantation, 2019, 19, 2805-2813.	2.6	32
47	Impact of HLA Compatibility on Lung Transplant Survival and Evidence for an HLA Restriction Phenomenon: A Collaborative Transplant Study Report. Transplantation, 2010, 90, 912-917.	0.5	31
48	SERIAL PERIPHERAL BLOOD INTERLEUKIN-18 AND PERFORIN GENE EXPRESSION MEASUREMENTS FOR PREDICTION OF ACUTE KIDNEY GRAFT REJECTION. Transplantation, 2004, 77, 1589-1595.	0.5	30
49	Donor-specific antibodies require preactivated immune system to harm renal transplant. EBioMedicine, 2016, 9, 366-371.	2.7	30
50	Release of Soluble CD30 After Allogeneic Stimulation Is Mediated by Memory T Cells and Regulated by IFN- \hat{I}^3 and IL-2. Transplantation, 2013, 96, 154-161.	0.5	28
51	Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Human Immunology, 2007, 68, 652-660.	1.2	26
52	Role and Value of Luminex $\hat{A}^{\text{@}}$ -Detected HLA Antibodies before and after Kidney Transplantation. Transfusion Medicine and Hemotherapy, 2013, 40, 190-195.	0.7	25
53	Prevention of antibody-mediated kidney transplant rejection. Transplant International, 2012, 25, 633-645.	0.8	24
54	Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atherosclerosis Supplements, 2013, 14, 199-202.	1.2	23

#	Article	IF	CITATIONS
55	The possible critical role of T-cell help in DSA-mediated graft loss. Transplant International, 2018, 31, 577-584.	0.8	23
56	Kidneys From Elderly Deceased Donorsâ€"Is 70 the New 60?. Frontiers in Immunology, 2019, 10, 2701.	2.2	23
57	Serum sCD30 in Monitoring of Alloresponse in Well HLA-Matched Cadaveric Kidney Transplantations. Transplantation, 2005, 80, 1809-1812.	0.5	22
58	Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2. Kidney International, 2021, 100, 700-702.	2.6	22
59	Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 98-106.	2.2	22
60	CD4+ Lymphocyte Depletion in HIVâ€Infected Patients is Associated with gp120â€Immunoglobulinâ€Complement Attachment to CD4+ Cells. Vox Sanguinis, 1993, 64, 31-36.	0.7	21
61	The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clinical Transplantation, 2003, 17, 217-224.	0.8	21
62	Evaluation of T-Cell Receptor Repertoires in Patients with Long-Term Renal Allograft Survival. American Journal of Transplantation, 2005, 5, 746-756.	2.6	21
63	Critical evaluation of a possible role of HLA epitope matching in kidney transplantation. Transplantation Reviews, 2020, 34, 100533.	1.2	21
64	Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival. Transplantation, 2019, 103, 581-587.	0.5	20
65	Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation. Frontiers in Immunology, 2019, 10, 3142.	2.2	20
66	The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. Nature Medicine, 2022, 28, 989-998.	15.2	20
67	Impact of HLA Matching and HLA Antibodies in Organ Transplantation: A Collaborative Transplant Study View. Methods in Molecular Biology, 2012, 882, 267-277.	0.4	19
68	Differential Influence of Donor Age Depending on the Indication for Liver Transplantationâ€"A Collaborative Transplant Study Report. Transplantation, 2020, 104, 779-787.	0.5	19
69	Outcomes and complications following ABOâ€incompatible kidney transplantation performed after desensitization by semiâ€selective immunoadsorption ―a retrospective study. Transplant International, 2019, 32, 1286-1296.	0.8	18
70	Isotypes and IgG Subclasses of Antiâ€Fab Antibodies in Human Immunodeficiency Virusâ€Infected Hemophilia Patients. Vox Sanguinis, 1994, 66, 37-45.	0.7	17
71	Clinical Relevance of HLA Antibodies in Kidney Transplantation: Recent Data from the Heidelberg Transplant Center and the Collaborative Transplant Study. Journal of Immunology Research, 2017, 2017, 1-7.	0.9	17
72	Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis. United European Gastroenterology Journal, 2018, 6, 255-262.	1.6	17

#	Article	IF	CITATIONS
73	Association of graft survival with tacrolimus exposure and late intraâ€patient tacrolimus variability in pediatric and young adult renal transplant recipients—an international CTS registry analysis. Transplant International, 2020, 33, 1681-1692.	0.8	17
74	Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients. Pediatric Nephrology, 2021, 36, 2473-2484.	0.9	16
75	Posttransplant sCD30 as a biomarker to predict kidney graft outcome. Clinica Chimica Acta, 2012, 413, 1350-1353.	0.5	15
76	Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation. Transplantation, 2018, 102, 845-852.	0.5	15
77	Neutralizing antibody activity against the B.1.617.2 (delta) variant 8Âmonths after two-dose vaccination with BNT162b2 in health care workers. Clinical Microbiology and Infection, 2022, 28, 1024.e7-1024.e12.	2.8	15
78	Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients. Frontiers in Immunology, 2022, 13, 840136.	2.2	15
79	Does Borderline Kidney Allograft Rejection Always Require Treatment?. Transplantation, 2010, 90, 427-432.	0.5	14
80	Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transplant International, 2013, 26, 331-338.	0.8	14
81	Can PIRCHE-II Matching Outmatch Traditional HLA Matching?. Frontiers in Immunology, 2021, 12, 631246.	2.2	14
82	Progressive improvement in shortâ€; medium―and longâ€ŧerm graft survival in kidney transplantation patients in Ireland – a retrospective study. Transplant International, 2019, 32, 974-984.	0.8	12
83	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	0.8	12
84	Impact of HLA compatibility in recipients of kidneys from expanded criteria donors: A Collaborative Transplant Study Report. International Journal of Immunogenetics, 2021, 48, 201-210.	0.8	12
85	ATG induction in renal transplant recipients: Long-term hazard of severe infection is associated with long-term functional T cell impairment but not the ATG-induced CD4 cell decline. Human Immunology, 2014, 75, 561-569.	1.2	11
86	Pretransplant human leukocyte antigen antibodies detected by single-antigen bead assay are a risk factor for long-term kidney graft loss even in the absence of donor-specific antibodies. Transplant International, 2016, 29, 988-998.	0.8	11
87	Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2. Frontiers in Medicine, 2021, 8, 721286.	1.2	11
88	Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. Transplant Immunology, 2011, 25, 72-76.	0.6	10
89	Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. Journal of Dermatological Science, 2015, 77, 37-45.	1.0	10
90	No Increase in Colon Cancer Risk Following Induction with Neu5Gc-Bearing Rabbit Anti-T Cell IgG (ATG) in Recipients of Kidney Transplants. Cancers, 2018, 10, 324.	1.7	10

#	Article	IF	CITATIONS
91	Relevance of donorâ€specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center. Hla, 2019, 94, 11-15.	0.4	10
92	Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure. Human Immunology, 2012, 73, 1102-1108.	1.2	9
93	Circulating and urinary microRNAs as possible biomarkers in kidney transplantation. Transplantation Reviews, 2018, 32, 110-118.	1.2	8
94	Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation. Frontiers in Immunology, 2020, 11, 1886.	2.2	8
95	Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk. Pediatric Nephrology, 2022, 37, 2503-2514.	0.9	8
96	Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome. Frontiers in Immunology, 2022, 13, 829228.	2.2	8
97	Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients. Kidney International, 2022, 101, 639-642.	2.6	8
98	Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch?. Langenbeck's Archives of Surgery, 2011, 396, 467-474.	0.8	7
99	Influence of cold ischemia time on the outcome of kidney transplants from donors aged 70 years and above – A Collaborative Transplant Study Report. Transplantation, 2021, Publish Ahead of Print, 2461-2469.	0.5	7
100	Heart transplantation across preformed donor-specific antibody barriers using a perioperative desensitization protocol. American Journal of Transplantation, 2022, 22, 2064-2076.	2.6	7
101	Increased Soluble Fas in HIV-Infected Hemophilia Patients with CD4+and CD8+Cell Count Increases and Viral Load and Immune Complex Decreases. AIDS Research and Human Retroviruses, 2001, 17, 329-335.	0.5	6
102	HLA antibody screening in kidney transplantation: current guidelines. Langenbeck's Archives of Surgery, 2014, 399, 415-420.	0.8	6
103	An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. Expert Opinion on Pharmacotherapy, 2017, 18, 799-807.	0.9	6
104	Outcome of Extended Right Lobe Liver Transplantations. Liver Transplantation, 2022, 28, 807-818.	1.3	6
105	Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy. Journal of Clinical Medicine, 2022, 11, 1739.	1.0	6
106	Recognition of defined epitopes by affinity-purified anti-immunoglobulin Fab autoantibodies isolated from HIV-infected humans., 1999, 12, 169-176.		5
107	Virtual PRA replaces traditional PRA: small change but significantly more justice for sensitized patients. Transplant International, 2015, 28, 708-709.	0.8	5
108	Increased risk of infection-associated death with incompatible kidney transplantations. Transplant International, 2017, 30, 1209-1211.	0.8	5

#	Article	IF	CITATIONS
109	Pulse Pressure and Outcome in Kidney Transplantation: Results From the Collaborative Transplant Study. Transplantation, 2019, 103, 772-780.	0.5	5
110	Higher CD19+CD25+ Bregs are independently associated with better graft function in renal transplant recipients. BMC Nephrology, 2021, 22, 180.	0.8	5
111	Analysis of de novo donorâ€specific <scp>HLAâ€DPB1</scp> antibodies in kidney transplantation. Hla, 2021, 98, 423-430.	0.4	5
112	Desensitization and survival in kidney transplant recipients. Nature Reviews Nephrology, 2017, 13, 196-198.	4.1	4
113	Is There a Need for Additional DQ Matching?. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 683-684.	2.2	4
114	Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Frontiers in Immunology, 2021, 12, 724331.	2.2	4
115	Maternal versus paternal living kidney transplant donation is associated with lower rejection in young pediatric recipients: A Collaborative Transplant Study report. Pediatric Transplantation, 2021, , e14154.	0.5	4
116	Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion. Atherosclerosis Supplements, 2019, 40, 68-72.	1.2	3
117	Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients. Immunity, Inflammation and Disease, 2021, 9, 1252-1271.	1.3	3
118	Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report. Frontiers in Surgery, 2021, 8, 678392.	0.6	3
119	Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption. Frontiers in Medicine, 2021, 8, 781491.	1.2	3
120	Current pharmacotherapeutical options for the prevention of kidney transplant rejection. Expert Opinion on Pharmacotherapy, 2013, 14, 1029-1041.	0.9	2
121	Editorial: Transplantation of Marginal Organsâ€"Immunological Aspects and Therapeutic Perspectives. Frontiers in Immunology, 2020, 11, 612576.	2.2	2
122	Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients. Transplant International, 2021, 35, 10071.	0.8	2
123	Reply to Focosi and Boggi. Transplantation, 2011, 92, e15-e16.	0.5	1
124	Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease. Human Immunology, 2016, 77, 403-410.	1.2	1
125	Clinical outcomes after ABO-incompatible renal transplantation. Lancet, The, 2019, 394, 1989.	6.3	1
126	Three is not enough. Transplant International, 2020, 33, 612-614.	0.8	1

#	Article	IF	CITATIONS
127	Low Pre-Transplant Caveolin-1 Serum Concentrations Are Associated with Acute Cellular Tubulointerstitial Rejection in Kidney Transplantation. Molecules, 2021, 26, 2648.	1.7	1
128	Influence of Calcineurin Inhibitor Choice on Outcomes in Kidney Transplant Recipients Aged ≥60 Y: A Collaborative Transplant Study Report. Transplantation, 2022, 106, e212-e218.	0.5	1
129	Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer. Progress in Transplantation, 2017, 27, 365-368.	0.4	O
130	SP698OUTCOMES FOLLOWING LIVING DONOR KIDNEY TRANSPLANTATION IN PATIENTS WITH DONOR-SPECIFIC HLA ANTIBODIES AFTER DESENSITIZATION WITH IMMUNOADSORPTION. Nephrology Dialysis Transplantation, 2018, 33, i582-i582.	0.4	0
131	SaOO11A PHASE-I CLINICAL TRIAL OF DONOR-DERIVED MIC CELL INFUSION FOR THE INDUCTION OF DONOR-SPECIFIC HYPORESPONSIVENESS AFTER LIVING DONOR KIDNEY TRANSPLANTATION (TOL-1 STUDY). Nephrology Dialysis Transplantation, 2018, 33, i320-i320.	0.4	0
132	Is Belatacept Switch Safe in Renal Transplant Recipients With Donor-specific Antibodies?. Transplantation, 2019, 103, 1984-1985.	0.5	0
133	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion — a Phase I Study (TOL-1). Blood, 2018, 132, 4539-4539.	0.6	0
134	Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies. Pediatric Nephrology, 2021, 36, 725-729.	0.9	0
135	Kidney Transplants from Elderly Donors: The Experience of a Reference Center in Croatia. Experimental and Clinical Transplantation, 2022, 20, 19-27.	0.2	0